Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 4/20 | 0.57 |
| ▸ | NPY4R | P50391 | 11/20 | 0.56 |
| ▸ | NPY1R | P25929 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 6/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.56 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827583 | 0.95 | NPY4R (0.59) | VIPR1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30792531 | 0.93 | VIPR1 (0.59) | VIPR1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30092922 | 0.90 | NPY4R (0.54) | VIPR1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31211669 | 0.89 | VIPR2 (0.62) | VIPR1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30092917 | 0.89 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30810167 | 0.88 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30974522 | 0.88 | VIPR1 (0.61) | VIPR1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29901562 | 0.88 | NPY4R (0.69) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL29770022 | 0.87 | NPY4R (0.69) | VIPR1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29770014 | 0.87 | NPY4R (0.69) | VIPR1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | VEGFA, FLT4, FLT1 | VIPR1 6/4885NPY4R 62/4885NPY1R 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.